blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2758134

EP2758134 - BUPRENORPHINE FOR THE TREATMENT OF ACUTE SUICIDALITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.04.2020
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  26.04.2019
FormerGrant of patent is intended
Status updated on  28.01.2019
FormerExamination is in progress
Status updated on  23.11.2018
FormerGrant of patent is intended
Status updated on  29.07.2018
FormerExamination is in progress
Status updated on  25.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Carmel - Haifa University Economic Corporation Ltd.
Eshkol Building, 25th Floor, Room 2502
Haifa University
3498838 Haifa / IL
[2019/22]
Former [2018/34]For all designated states
Carmel - Haifa University Economic Corporation Ltd.
Eshkol Building, 29th Floor, Room 2904
Haifa University
31905 Haifa / IL
Former [2014/31]For all designated states
Carmel - Haifa University Economic Corp Ltd.
Eshkol Tower
29th Floor Room 2904
Haifa University
Mount Carmel
31905 Haifa / IL
Inventor(s)01 / YOVELL, Yoram
33 HaNarkis Street
90805 Mevaseret Zion / IL
 [2014/31]
Representative(s)Dennemeyer & Associates S.A.
Postfach 70 04 25
81304 München / DE
[2019/22]
Former [2014/31]Dennemeyer & Associates S.A.
Poccistrasse 11
80336 München / DE
Application number, filing date12833132.919.09.2012
[2019/22]
WO2012IB54971
Priority number, dateUS201161536081P19.09.2011         Original published format: US 201161536081 P
[2014/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013042054
Date:28.03.2013
Language:EN
[2013/13]
Type: A1 Application with search report 
No.:EP2758134
Date:30.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 28.03.2013 takes the place of the publication of the European patent application.
[2014/31]
Type: B1 Patent specification 
No.:EP2758134
Date:29.05.2019
Language:EN
[2019/22]
Search report(s)International search report - published on:US28.03.2013
(Supplementary) European search report - dispatched on:EP13.02.2015
ClassificationIPC:A61K31/485, A61P25/24, A61P25/00
[2018/33]
CPC:
A61K31/485 (EP,US); A61P25/00 (EP); A61P25/24 (EP)
Former IPC [2015/12]A61P25/24, A61P25/00
Former IPC [2014/31]A61P25/24
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/31]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BUPRENORPHIN ZUR BEHANDLUNG VON AKUTER SUIZIDALITÄT[2014/31]
English:BUPRENORPHINE FOR THE TREATMENT OF ACUTE SUICIDALITY[2014/31]
French:BUPRÉNORPHINE POUR LE TRAITEMENT D'UNE TENDANCE SUICIDAIRE AIGUË[2014/31]
Entry into regional phase09.04.2014National basic fee paid 
09.04.2014Search fee paid 
09.04.2014Designation fee(s) paid 
09.04.2014Examination fee paid 
Examination procedure09.04.2014Examination requested  [2014/31]
07.09.2015Amendment by applicant (claims and/or description)
24.11.2016Despatch of a communication from the examining division (Time limit: M04)
30.03.2017Reply to a communication from the examining division
11.09.2017Despatch of a communication from the examining division (Time limit: M04)
12.01.2018Reply to a communication from the examining division
30.07.2018Communication of intention to grant the patent
19.11.2018Fee for grant paid
19.11.2018Fee for publishing/printing paid
20.11.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
29.01.2019Communication of intention to grant the patent
16.04.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.11.2016
Opposition(s)03.03.2020No opposition filed within time limit [2020/19]
Fees paidRenewal fee
26.09.2014Renewal fee patent year 03
25.09.2015Renewal fee patent year 04
22.09.2016Renewal fee patent year 05
26.09.2017Renewal fee patent year 06
25.09.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.09.2012
AL29.05.2019
AT29.05.2019
CY29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
MK29.05.2019
MT29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
IS29.09.2019
BE30.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
[2022/31]
Former [2021/34]HU19.09.2012
AL29.05.2019
AT29.05.2019
CY29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
MT29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
IS29.09.2019
BE30.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2021/32]HU19.09.2012
AL29.05.2019
AT29.05.2019
CY29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
IS29.09.2019
BE30.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2021/31]AL29.05.2019
AT29.05.2019
CY29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
IS29.09.2019
BE30.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2021/26]AL29.05.2019
AT29.05.2019
CY29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
BE30.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2020/38]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
BE30.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2020/36]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
IE19.09.2019
LU19.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2020/35]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
LU19.09.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2020/34]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
CH30.09.2019
LI30.09.2019
PT30.09.2019
Former [2020/25]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
MC29.05.2019
NL29.05.2019
PL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SI29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/17]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SK29.05.2019
SM29.05.2019
TR29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/14]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SK29.05.2019
SM29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/12]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
IT29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SK29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/11]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
EE29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
SK29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/10]AL29.05.2019
AT29.05.2019
CZ29.05.2019
DK29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RO29.05.2019
RS29.05.2019
SE29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/09]AL29.05.2019
CZ29.05.2019
DK29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RS29.05.2019
SE29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2020/07]AL29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
LV29.05.2019
NL29.05.2019
RS29.05.2019
SE29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2019/51]AL29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
LV29.05.2019
RS29.05.2019
SE29.05.2019
BG29.08.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2019/50]AL29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
LV29.05.2019
RS29.05.2019
SE29.05.2019
NO29.08.2019
GR30.08.2019
PT30.09.2019
Former [2019/49]AL29.05.2019
ES29.05.2019
FI29.05.2019
HR29.05.2019
LT29.05.2019
SE29.05.2019
NO29.08.2019
PT30.09.2019
Former [2019/48]ES29.05.2019
FI29.05.2019
LT29.05.2019
SE29.05.2019
NO29.08.2019
PT30.09.2019
Former [2019/47]ES29.05.2019
FI29.05.2019
LT29.05.2019
NO29.08.2019
Documents cited:Search[X]  - ANGELO GIOVANNI ICRO MAREMMANI ET AL, "Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?", ANNALS OF GENERAL PSYCHIATRY, BIOMED CENTRAL, LONDON, GB, (20110515), vol. 10, no. 1, doi:10.1186/1744-859X-10-17, ISSN 1744-859X, page 17, XP021101199 [X] 1-15 * Conclusions. *

DOI:   http://dx.doi.org/10.1186/1744-859X-10-17
 [A]  - MAREMMANI ET AL, "Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients", JOURNAL OF SUBSTANCE ABUSE TREATMENT, PERGAMON PRESS, NEW YORK, US, (20070701), vol. 33, no. 1, doi:10.1016/J.JSAT.2006.11.009, ISSN 0740-5472, pages 91 - 98, XP022121481 [A] 1-15 * paragraph [03.2] *

DOI:   http://dx.doi.org/10.1016/j.jsat.2006.11.009
International search[Y]WO03079945  (EURO CELTIQUE SA [LU], et al);
 [A]WO2005055996  (FOREST LABORATORIES [US], et al);
 [A]US2006216340  (REDER ROBERT F [US], et al);
 [Y]US2010048535  (SLATER KENNETH C [US], et al);
 [A]US2011039926  (MANSUY LUCILLA [FR]);
 [X]  - ABARBANEL MENTAL HEALTH CENTER, "A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality", CLINICALTRIALS.GOV, (20090316), URL: http://clinicaltrials.gov/ct2/show/NCT00863291, (20130103), XP003027798
by applicantUS6528518
 US2004181475
 US2004242974
 US8173695
    - BERTOLOTE ET AL., SUICIDOLOGY, (2002), vol. 2, pages 6 - 8
    - GUNNELL; ASHBY, BMJ, (2004), vol. 329, pages 34 - 38
    - BEASLEY ET AL., BMJ, (1991), vol. 303, pages 685 - 692
    - KAHN ET AL., J CLIN PSYCHIATRY, (2003), vol. 160, pages 790 - 792
    - HAMMAD ET AL., ARCH GEN PSYCHIATRY, (2006), vol. 63, pages 332 - 339
    - JICK ET AL., JAMA, (2004), vol. 292, pages 338 - 343
    - JUURLINK ET AL., AM J PSYCHIATRY, (2006), vol. 163, pages 813 - 821
    - LONNQVIST, Suicidology and suicide prevention, (2009), pages 275 - 286
    - KEILP ET AL., JAFFECIVE DISORDERS, (2012), vol. 140, pages 75 - 81
    - ORBACH ET AL., SUICIDE LIFE THREAT BEHAV, (2003), vol. 33, pages 231 - 241
    - EISENBERGER; LIEBERMAN, TRENDS COGN SCI, (2004), vol. 8, pages 294 - 300
    - KROSS ET AL., PROC NATL ACAD SCI USA, (2011), vol. 108, pages 6270 - 6275
    - DEWALL ET AL., PSYCHOLOGICAL SCIENCE, (2010), vol. 21, page 931
    - SPORER, ANN EMERG MED, (2004), vol. 43, pages 580 - 584
    - BODKIN ET AL., J CLIN PSYCHOPHARMACOL, (1995), vol. 15, pages 49 - 57
    - EMRICH ET AL., ANN NY ACAD SCI, (1982), vol. 398, pages 108 - 112
    - MORGAN; CALLAWAY, BIOL PSYCHIATRY, (1990), vol. 28, pages 1078 - 1080
    - KOSTEN ET AL., J SUBST ABUSE TREAT, (1990), vol. 7, pages 51 - 54
    - CALLAWAY, BIOL PSYCHIATRY, (1996), vol. 39, pages 989 - 990
    - MAREMMANI ET AL., HEROIN ADD REL CLIN PROBL, (2006), vol. 8, pages 31 - 48
    - STANLEY; SIEVER, AM J PSYCHIATRY, (2010), vol. 167, pages 24 - 39
    - "Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?", ANGELO GIOVANNI ICRO MAREMMANI ET AL., ANNALS OF GENERAL PSYCHIATRY, BIOMED CENTRAL, (20110515), vol. 10, page 17
    - "Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients", MAREMMANI ET AL., JOURNAL OF SUBSTANCE ABUSE TREATMENT, PERGAMON PRESS, (20070701), vol. 33, pages 91 - 98
    - BIRGE ET AL., J PHARM SCI, (1977), vol. 66, pages 1 - 19
    - POSNER ET AL., CNS SPECTR, (2007), vol. 12, pages 156 - 162
    - COCCARO ET AL., JNEUROPSYCHIATRY CLIN NEUROSCI, (1991), vol. 3, pages 44 - 51
    - HOLDEN ET AL., CANADIAN J BEHAV SCI, (2001), vol. 33, pages 224 - 232
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO.
    - COCCARO ET AL., J NEUROPSYCHIATRY CLIN NEUROSCI, (1991), vol. 3, pages 44 - 51
    - BECK ET AL., J PERS ASSESS, (1996), vol. 67, pages 588 - 597
    - "Clinical Global Impressions", GUY ET AL., ECDEU Assessment Manual for Psychopharmacology, NATIONAL INSTITUTE OF MENTAL HEALTH, (1976), pages 218 - 222
    - MIKULINCER; EREV, BR J SOC PSYCHOL, (1991), vol. 30, pages 273 - 291
    - MIKULINCER ET AL., J PERS SOC PSYCHOL, (1990), vol. 58, pages 273 - 280
    - BUCKLEY ET AL., J SUBST ABUSE TREAT, (2001), vol. 20, pages 197 - 204
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.